Risk factor
Very high price volatility
Profitability factor
Very weak growth
About
Sugentech Inc., a South Korean firm, develops and markets advanced in-vitro diagnostic (IVD) systems and products worldwide. Their solutions integrate biotechnology, information technology, and nanotechnology. The company's diverse portfolio features sophisticated Multiplex BLOT disease diagnostic platforms, including automated immunoblot processors and molecular diagnostic tools, alongside various test kits. They also offer a range of convenient self-testing products, such as digital ovulation, pregnancy, and early pregnancy detection kits, as well as mobile testing options. Additionally, Sugentech provides point-of-care (POC) analyzers and tests for a broad spectrum of conditions, from infectious diseases like M.tuberculosis, M.bovis, SARS-CoV-2 (antibodies and antigens), and influenza A/B, to critical biomarkers such as CRP/hsCRP/dualCRP, procalcitonin, troponin I, hemoglobinA1c, and human chorionic gonadotropin. Founded in 2011, the company, originally named Accugen Healthcare, Inc., adopted its current name, Sugentech Inc., in October 2013 and is headquartered in Daejeon.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers.